	US 12,491,210 B2
	Methods of assessing and treating autism spectrum disorders using human umbilical cord tissue-derived mesenchymal stromal cells
Joanne Kurtzberg, Durham, NC (US); Geraldine Dawson, Durham, NC (US); and Jessica Sun, Durham, NC (US)
Assigned to Duke University, Durham, NC (US)
Appl. No. 17/044,843
Filed by DUKE UNIVERSITY, Durham, NC (US)
PCT Filed Apr. 4, 2019, PCT No. PCT/US2019/025716 § 371(c)(1), (2) Date Oct. 1, 2020, PCT Pub. No. WO2019/195506, PCT Pub. Date Oct. 10, 2019.
Claims priority of provisional application 62/652,722, filed on Apr. 4, 2018.
Prior Publication US 2021/0128631 A1, May 6, 2021
Int. Cl. A61K 35/28 (2015.01); A61K 9/00 (2006.01); A61P 25/00 (2006.01)

CPC A61K 35/28 (2013.01) [A61K 9/0019 (2013.01); A61P 25/00 (2018.01)]

15 Claims

1. A method of treating a patient having or suspected of having an autism spectrum disorder, the method comprising administering a therapeutically effective amount of human allogeneic cord tissue-derived mesenchymal stromal cells (allogeneic hCT-MSCs) to the patient, wherein the therapeutically effective dose of allogeneic hCT-MSCs comprises a total of 6.0×10⁶cells/kg, and is administered in 2 to 3 doses within 6 months.